While targeted therapies have revolutionized cancer treatment, several challenges remain:
Development of resistance: Cancer cells can develop resistance to targeted therapies through additional mutations or activation of alternative pathways. Heterogeneity: Tumors are often heterogeneous, containing a mix of different cell populations with varying genetic profiles, complicating treatment. Limited targets: Not all cancers have identifiable targetable mutations, limiting the applicability of targeted therapies.
